tolerability profile, low side effects and complication rates. Moreover, the positive predictive value is quite high. As adequacy of biopsy specimen and pathological diagnosis improve, the only limitations to a systematic utilization of renal biopsy might be those eloquent radiologic aspects that are highly reliable on differentiating benign from non-benign lesions.
INTRODUCTION AND OBJECTIVES:
The tumor:cortex peak early-phase enhancement ratio (PEER) using multiphase CT has been prospectively validated for discerning CD117(þ) chromophobe RCC from CD117(þ) oncocytoma. We evaluate the effectiveness of routine preoperative biopsy and PEER evaluation to prevent resection of benign kidney tumors.
METHODS: We retrospectively reviewed the pathology of all fat poor renal cortical tumors resected over a 5 year period by a single surgeon at a National Comprehensive Cancer Care Network institute who used the approach of routine biopsy combined with oncocytic tumor:cortex PEER evaluation to select patients for surgical resection. Biopsy was routinely performed for any renal cortical tumors with suspicion of benign histology. Biopsy showing benign oncocytoma were observed. CD117 positive oncocytic tumors suggestive of oncocytoma were confirmed to be oncocytoma on a tumor:cortex PEER value of more than 0.55.
We looked at pathology of all resected renal cortical tumors over a 6 year period using this approach to determine the incidence of benign vs malignant histology.
In parallel, we also determined the number of patients with benign renal tumor suggested on biopsy who went on active surveillance and avoided initial resection using this approach. Outcomes of benign tumor on surveillance, including progression and metastasis rates were reviewed.
RESULTS: 167 patients with a preoperative diagnosis of renal cell carcinoma underwent surgery. 106 (63.47%) patients were diagnosed as malignant renal tumor on preoperative biopsy. 61 (36.52%) patients with frank features of malignancy clinically or on imaging directly proceeded to surgery without a biopsy. On review of the final resected tumor histopathology, no instance of resection for a benign tumor was found. One patient with a preoperative diagnosis of spindle cell tumor was found to have Epitheloid Angiomyolipoma with necrosis and indeterminate malignant potential on final pathology. During the same period, 35 patients were determined to have benign renal tumor on biopsy and PEER evaluation. These patients did not undergo surgery and were placed on surveillance. Over a median follow up of 24 months, no patient developed progression or metastasis.
CONCLUSIONS: A combination of routine biopsy for tumors with potential for benign histology and the PEER approach for discerning CD117(þ) oncocytoma from CD117(þ) chromophobe RCC is an effective diagnostic tool to avoid resection for benign tumors. 
In patients diagnosed with a small organ-confined renal cell carcinoma, there is a paucity of potential biomarkers able to predict cancer aggressiveness. The aim of this pilot study is to investigate the applicability of a radio-genomic approach in the assessment and diagnosis of small renal masses.
METHODS: To establish the viability of conducting a combined analysis of both radiomic and genomic data, a pilot cohort of 6 patients with < 5cm G2 unilateral non-metastatic T1a-b clearcell renal cell carcinoma (ccRCC), who underwent surgery was evaluated. Transcriptomic analysis was conducted through RNA-seq, while radiomic data was extracted from pre-operative 4 phase contrastenhanced multidetector CT scans. Genomic heterogeneity was assessed with principal component analysis (PCA) run on unrestricted data, on a ccRCC-associated gene list and on centred Reads Per Kilobase of transcript, per Million mapped reads values. The underlying pathways and gene ontologies were established with enrichment analysis. In addition, Pearson's correlation between radiomic data and the transcription of ccRCC significant genes was fitted, and the resulting data plotted using dendrogram and heatmap plots.
RESULTS: Even in a clinically homogeneous population, the PCA and the enrichment analysis have demonstrated that RCC should be regarded as an intrinsically heterogeneous disease. The analysis of the radiomic features and gene expression correlation using heatmap (fig 1) and dendrogram (fig 2) showed two distinct radiogenomic correlation patterns: the former including 5 distinct radiomic features, and the latter including 2 features.
CONCLUSIONS: The current pilot study is the first investigation demonstrating an innovative radiogenomic characterisation of ccRCC. Based on such observations, further investigation into the radiomic and genomic approaches for the enhanced diagnosis of renal cancer is warranted.
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MP14-08 INITIAL OUTCOMES FOR UNIVERSAL ACTIVE SURVEILLANCE OF SMALL RENAL MASSES USING PRE-DEFINED PROGRESSION CRITERIA FOR TREATMENT CONVERSION
Arun Menon*, Aly Ahmed, Tashionna White, Gaybrielle James, Paul May, Eric Kauffman, Buffalo, NY INTRODUCTION AND OBJECTIVES: Metastatic risk for small renal mass (SRM) patients on active surveillance (AS) is low and often outweighed by treatment morbidity/mortality. Current AS literature is confounded by highly selected SRM patients who are unfit to receive treatment, hence treatment rates and progression criteria for triggering treatment in healthier patients are not well defined. We report our initial
